Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells

[1]  M. Schimek,et al.  Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia. , 2017, Blood.

[2]  Yanli Jin,et al.  Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib , 2016, Theranostics.

[3]  B. Kaina,et al.  Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance. , 2016, Cancer research.

[4]  Qi-En Wang.  DNA damage responses in cancer stem cells: Implications for cancer therapeutic strategies. , 2015, World journal of biological chemistry.

[5]  Z. Ning,et al.  Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  J. Li,et al.  A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor. , 2015, Current cancer drug targets.

[7]  Kun Zhang,et al.  Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells. , 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[8]  S. Gerson,et al.  CD133+ cells contribute to radioresistance via altered regulation of DNA repair genes in human lung cancer cells. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  Yingjie Guo,et al.  Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells. , 2013, Biochemical and biophysical research communications.

[10]  P. Xing,et al.  Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas , 2012, Cancer Chemotherapy and Pharmacology.

[11]  Lesley A. Mathews,et al.  Increased Expression of DNA Repair Genes in Invasive Human Pancreatic Cancer Cells , 2011, Pancreas.

[12]  M. Hedayati,et al.  Downregulation of Homologous Recombination DNA Repair Genes by HDAC Inhibition in Prostate Cancer Is Mediated through the E2F1 Transcription Factor , 2010, PloS one.

[13]  Wei Zhao,et al.  A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells. , 2010, Biochemical and biophysical research communications.

[14]  Bolin Liu,et al.  Experimental Therapeutics, Molecular Targets, and Chemical Biology Hdac Inhibitor Sndx-275 Induces Apoptosis in Erbb2-overexpressing Breast Cancer Cells via Down-regulation of Erbb3 Expression , 2022 .

[15]  E. Colado,et al.  The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair , 2009, Leukemia.

[16]  G. Kao,et al.  The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer , 2009, Molecular Cancer Therapeutics.

[17]  Jorge A. Almenara,et al.  Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions , 2008, Molecular Cancer Therapeutics.

[18]  Daniel Medina,et al.  Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. , 2008, Cancer research.

[19]  Ching-Yu Chen,et al.  Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. , 2007, Cancer research.

[20]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[21]  A. Scarpa,et al.  Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation , 2006, Virchows Archiv.

[22]  M. Ogura,et al.  A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma , 2015, International Journal of Hematology.

[23]  S. Grant,et al.  Histone deacetylase inhibitors and rational combination therapies. , 2012, Advances in cancer research.

[24]  Chunlei Zhang,et al.  Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). , 2007, Blood.

[25]  H. Kantarjian,et al.  Acute myeloid leukemia , 2018, Methods in Molecular Biology.